C3-Carbon Linked Glutarimide Degronimers for Target Protein Degradation
Summary
The USPTO granted Patent US12605450B2 to C4 Therapeutics, Inc. covering C3-carbon linked glutarimide Degronimers designed for targeted protein degradation via E3 Ubiquitin Ligase mechanisms. The patent contains 17 claims and names eight inventors including Andrew J. Phillips, Christopher G. Nasveschuk, and James A. Henderson. This grant establishes enforceable exclusive rights for the assignee in the pharmaceutical compounds and methods of use defined by the patent claims.
“This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.”
About this source
GovPing monitors USPTO Patent Grants - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 29 changes logged to date.
What changed
The USPTO issued Patent US12605450B2 to C4 Therapeutics, Inc. for C3-carbon linked glutarimide Degronimers with E3 Ubiquitin Ligase targeting moieties capable of linking to protein-targeting ligands for in vivo degradation. This grant confers legally enforceable exclusive rights to the patent holder for the compositions and methods described across 17 claims.
Pharmaceutical companies engaged in targeted protein degradation research should monitor this intellectual property to understand potential freedom-to-operate considerations. Companies developing similar molecular glues or PROTAC-style degraders may need to evaluate whether their technologies fall within the scope of this patent's claims.
Archived snapshot
Apr 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
C3-carbon linked glutarimide Degronimers for target protein degradation
Grant US12605450B2 Kind: B2 Apr 21, 2026
Assignee
C4 THERAPEUTICS, INC.
Inventors
Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Kiel Lazarski, Gesine Kerstin Veits, Harit U. Vora
Abstract
This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
CPC Classifications
A61K 47/545 A61K 31/45 A61K 31/451 A61K 31/454 A61K 31/4545 C07D 211/88 C07D 211/90
Filing Date
2024-04-22
Application No.
18642602
Claims
17
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.